Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer / 浙江大学学报(英文版)(B辑:生物医学和生物技术)
Journal of Zhejiang University. Science. B
; (12): 446-450, 2005.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-249192
Responsible library:
WPRO
ABSTRACT
To determine the pharmacokinetics of gemcitabine (2',2'-difluorodeoxycytidine) in Chinese non-small-cell lung cancer (NSCLC) patients. Six study subjects were administered gemcitabine at a fixed dose rate of 10 mg/m(2) per min (1200 mg/m(2), two hours infusion), and carboplatin and plasma gemcitabine concentrations were measured by ion-pair reversed-phase high-performance liquid chromatography (HPLC). 3P97 Pharmaceutical Kinetics Software was used for the calculation of pharmacokinetic parameters. The obtained mean parameters, elimination half life (t(1/2)) (10.67+/-3.38 min), area under the curve (AUC) (7.55+/-1.53 (microg x h)/ml), and clearance (CL) (3940.05+/-672.08 ml/min), were consistent with those reported in literature. The hematologic toxicology result showed that the regimen was effective on and tolerated by the patients.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Time Factors
/
Blood
/
Pharmacokinetics
/
China
/
Carcinoma, Non-Small-Cell Lung
/
Deoxycytidine
Type of study:
Prognostic study
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Zhejiang University. Science. B
Year:
2005
Document type:
Article